🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,196 results for “GE” Clear

  1. Cemiplimab

    Regeneron UK Limited

    Carcinoma, Non-Small-Cell Lung

    phase 2 small molecule active

    1 trial

  2. Cemiplimab

    Regeneron UK Limited

    Basal Cell Carcinoma (BCC)

    phase 2 small molecule active

    1 trial

  3. Cemiplimab

    Regeneron UK Limited

    Colorectal Cancer

    phase 2 small molecule active

    1 trial

  4. Cemiplimab

    Regeneron UK Limited

    Pleural Mesotheliomas

    phase 2 small molecule active

    1 trial

  5. Cemiplimab

    Regeneron UK Limited

    Bladder Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  6. Cemiplimab

    Regeneron UK Limited

    Metastatic Solid Tumor

    phase 2 small molecule active

    1 trial

  7. Cemiplimab

    Regeneron UK Limited

    High-Grade Glioma (HGG)

    phase 2 small molecule active

    1 trial

  8. Cemiplimab

    Regeneron UK Limited

    Hepatitis B Virus

    phase 2 mab terminated

    1 trial

  9. Cemiplimab

    Regeneron UK Limited

    Locally Recurrent Oral Cavity Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  10. Cemiplimab

    Regeneron UK Limited

    Colo-rectal Cancer

    phase 2 small molecule active

    1 trial

  11. Cemiplimab

    Regeneron UK Limited

    Hodgkin Lymphoma

    phase 2 small molecule terminated

    1 trial

  12. Cemiplimab

    Regeneron UK Limited

    Locally Advanced Basal Cell Carcinoma

    phase 2 mab active

    1 trial

  13. Cemiplimab

    Regeneron UK Limited

    Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  14. Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)]

    Regeneron UK Limited

    Colon Cancer

    phase 2 small molecule active

    1 trial

  15. Cemiplimab 350 MG Intravenous Solution

    Regeneron UK Limited

    Clear Cell Renal Cell Carcinoma

    phase 2 small molecule active

    1 trial

  16. Cemiplimab 350 mg i.v. on day 1 of every 21 days cycle for 2 cycles

    Regeneron UK Limited

    Merkel Cell Carcinoma, Stage I

    phase 2 small molecule active

    1 trial

  17. Cemiplimab Plus Gemcitabine

    Regeneron UK Limited

    Pancreatic Ductal Adenocarcinoma (mPDAC)

    phase 2 small molecule active

    1 trial

  18. Cemiplimab-Rwlc

    Regeneron UK Limited

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule terminated

    1 trial

  19. Cemiplimab-Rwlc

    Regeneron UK Limited

    Non-small Cell Lung Cancer Stage III

    phase 2 small molecule active

    1 trial

  20. Cemiplimab-Rwlc

    Regeneron UK Limited

    Cutaneous Squamous Cell Carcinoma

    phase 2 small molecule terminated

    2 trials

  21. Cenegermin, The placebo for investigational lyophilized cenegermin Drug Product is the same as the Drug Product with the exception that it does not contain cenegermin.

    Dompe' Farmaceutici S.p.A.

    Spastic Cerebral Palsy

    phase 2 small molecule active

    1 trial

  22. Cetuximab

    Merck KGaA, Darmstadt, Germany

    Metastatic Colorectal Cancer

    phase 2 small molecule completed

    1 trial

  23. Choice Of the Most Active Strategies for Short term recurring Triple Negative Breast Cancer A phase Ib/II, open-label, modular, dose-finding and dose-expansion study to explore safety, tolerability, pharmacokinetics, and anti-tumor activity of novel therapeutics in patients with early relapsed metastatic triple-negative breast cancer

    The George Institute

    Patients with hormone-receptor negative and HER2-negative (IHC 0, 1+ or IHC 2+/ISH-) breast cancer with early relapse while on (neo) adjuvant systemic treatment or within 12 months from the end of all treatments with curative intent.

    phase 2 other active

    1 trial

  24. Cisplatin

    Ultragenyx UK Limited

    Squamous Cell Carcinoma of the Anus

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources